Patient Characteristics (n = 10)
| No. of radioactive iodine therapy administrations | Accumulated dose | Target lesions | Mean thyroglobulin ± SD (ng/mL)* | Mean antithyroglobulin ± SD (IU/mL) | Mean growth rate of target lesions in 3 mo before study (mm/mo) | SPECT image (mean T/B ratio of target lesions) | |||||
| Patient no. | Pathologic type | GBq | mCi | Site | Total no. | 131I WBS | |||||
| 1 | PTC (follicular subtype) | 5 | 29.6 | 800 | Lung | 2 | Negative | 110.4 ± 34.9 | 25. 6 ± 11.4 | 0.998 | 9.8 |
| 2 | FTC | 7 | 33.3 | 900 | Lung | 2 | Negative | >1,000 | 47.4 ± 6.0 | 0.317 | 3.7 |
| 3 | FTC | 6 | 37 | 1,000 | Lung | 2 | Negative | >1,000 | 29.6 ± 3.4 | 0.463 | 8.1 |
| 4 | PTC (follicular subtype) | 3 | 16.65 | 450 | Mediastinum | 1† | Negative | 128.7 ± 18.8 | 20.3 ± 0.4 | NA‡ | 6.5 |
| 5 | PTC (follicular subtype) | 1 | 7.4 | 200 | Lung | 2 | Negative | >1,000 | 38.3 ± 0.1 | NA‡ | 5.4 |
| 6 | PTC (follicular subtype) | 7 | 40.7 | 1,100 | Bone and lymph nodes in pelvis | 2 | Negative | 42.9 ± 23.1 | 34.1 ± 6.4 | 0.140 | 3.3 |
| 7 | PTC | 3 | 16.65 | 450 | Lung | 1† | Negative | 0.5 ± 0.6 | 59.4 ± 10.4 | 0.403 | 5.3 |
| 8 | PTC | 2 | 11.1 | 300 | Lung | 2 | Negative | 26.9 ± 5.3 | 12.8 ± 2.8 | NA‡ | 4.6 |
| 9 | PTC | 5 | 33.3 | 900 | Lung | 2 | Negative | 481.2 ± 256.9 | 39.0 ± 75.0 | 0.350 | 3.7 |
| 10 | PTC | 1 | 7.4 | 200 | Bone | 2 | Negative | >1,000 | 118.5 ± 77.7 | 0.250 | 2.0 |
↵* Levels of serum thyroglobulin sometimes are interfered with by antithyroglobulin levels. Combination of the 2 is taken into consideration when thyroglobulin level stays normal while antithyroglobulin level stays high.
↵† Patients 4 and 7 had only 1 lesion analyzed because these patients had only 1 evaluable lesion according to RECIST 1.0.
↵‡ Dynamic follow-up of CT images in 3 mo before study was not available.
PTC = papillary thyroid cancer; FTC = follicular thyroid cancer.